Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prophylactic Dermovate for enfortumab vedotin-associated skin reactions
jRCTs051230118Completed
- Sponsor
- Astellas Pharma
- Start
- Nov 2023
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of clobetasol and enfortumab vedotin in cutaneous reaction and transitional cell carcinoma (TCC), sponsored by Astellas Pharma. Started Nov 2023; status: completed.
02
Drugs
clobetasolenfortumab vedotin
03
Conditions
cutaneous reactiontransitional cell carcinoma (TCC)
Beyond the preview
Go deeper on jRCTs051230118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051230118.